This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Generex Provides Update On Company Initiatives Including The AE37 Breast Cancer Vaccine Program

WORCESTER, Mass. and TORONTO, Nov. 13, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT) today provided the following update on company initiatives.

Antigen Express, Inc. ( www.antigenexpress.com), a wholly-owned subsidiary of Generex, is in late Phase II clinical development of a novel immunotherapeutic for breast cancer (AE37) that demonstrates promising trends in preventing relapse. The interim results of the large, controlled, randomized, and single blinded trial were the subject of an end of Phase II study report written for submission to the FDA with input from the Antigen Express AE37 Breast Cancer Vaccine Scientific Advisory Board (SAB) of Internationally-recognized experts in the field of breast cancer.

Based on this report, in response to the written request for the end of Phase II meeting with the FDA, the Company was given the option of proceeding expeditiously with the submission of a protocol for the Phase III study.  As the Phase III trial design has been established with the advice of the SAB, the Company is proceeding with the development of a full Phase III protocol, electing to do this under the auspices of a special protocol assessment (SPA). The SPA process was developed by the FDA as a means to ensure that the trial design and endpoints are acceptable to the agency and thereby expedite the approval process once the endpoints are met.

In particular, the specific population planned for the Phase III trial are those patients with low levels of expression of the HER2 oncoprotein who are not eligible for treatment with the drug Herceptin.  Representing a significant, unmet need in the management of breast cancer, this low-HER2 population is twice the size of the high-HER2 population (who are candidates for treatment with Herceptin).  Subject to the availability of funding, Antigen Express expects to initiate this Phase III trial in 2013.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,040.37 +29.69 0.16%
S&P 500 2,111.73 +4.34 0.21%
NASDAQ 5,082.9290 +12.9030 0.25%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs